WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522451
CAS#: 242478-38-2 (succinate)
Description: Solifenacin succinate is a competitive muscarinic receptor antagoinst used in treatment for an overactive bladder and reduces micturition, urgency, and incontinence. Solifenacin potently blocks signaling through M1, M2, and M3. Solifenacin prevents activation by acetylcholine, resulting in muscle relaxation.
MedKoo Cat#: 522451
Name: Solifenacin succinate
CAS#: 242478-38-2 (succinate)
Chemical Formula: C27H32N2O6
Exact Mass:
Molecular Weight: 480.56
Elemental Analysis: C, 67.48; H, 6.71; N, 5.83; O, 19.98
Synonym: YM 905; YM-905; YM905; Solifenacin succinate; brand name: Vesikur; Vesicare.
IUPAC/Chemical Name: [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;butanedioic acid
InChi Key: RXZMMZZRUPYENV-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H26N2O2.C4H6O4/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19;5-3(6)1-2-4(7)8/h1-9,18,21-22H,10-16H2;1-2H2,(H,5,6)(H,7,8)
SMILES Code: C1CN2CCC1C(C2)OC(=O)N3CCC4=CC=CC=C4C3C5=CC=CC=C5.C(CC(=O)O)C(=O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 480.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, Salemi JL, Shaw JD, Sullivan KL; Non-Motor Working Group of the Parkinson Study Group (PSG). Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism Relat Disord. 2015 May;21(5):514-20. doi: 10.1016/j.parkreldis.2015.02.025. Epub 2015 Mar 6. PubMed PMID: 25814050.
2: Shim M, Kim J, Park S, Choi SK, Lee SM, Huh KO, Song C, Choo MS, Ahn H. The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radical prostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study. Urology. 2015 May;85(5):1123-9. doi: 10.1016/j.urology.2015.01.022. Epub 2015 Mar 4. PubMed PMID: 25746580.
3: Han JY, Lee KS, Park WH, Park CH, Lee JG, Lee JZ, Kim DY, Na YG, Kwon DD, Choo MS. A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency. PLoS One. 2014 Nov 17;9(11):e112063. doi: 10.1371/journal.pone.0112063. eCollection 2014. PubMed PMID: 25401784; PubMed Central PMCID: PMC4234319.
4: Bianco FJ, Albala DM, Belkoff LH, Miles BJ, Peabody JO, He W, Bradt JS, Haas GP, Ahlering TE. A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy. J Urol. 2015 Apr;193(4):1305-10. doi: 10.1016/j.juro.2014.09.106. Epub 2014 Oct 2. PubMed PMID: 25281778.
5: Sekeroglu MA, Hekimoglu E, Petricli IS, Tasci Y, Dolen I, Arslan U. The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment. Int Urogynecol J. 2014 Nov;25(11):1479-82. doi: 10.1007/s00192-014-2396-8. Epub 2014 May 7. PubMed PMID: 24803216.
6: Huo LZ, Jing HG, Wang TC, Yuan SX, Luan XH, Guo KC, Shi BK. [A combination of solifenacin succinate and naftopidil in the treatment of female overactive bladder]. Zhonghua Yi Xue Za Zhi. 2013 Nov 26;93(44):3526-8. Chinese. PubMed PMID: 24521895.
7: Vecchioli-Scaldazza C, Morosetti C, Berouz A, Giannubilo W, Ferrara V. Solifenacin succinate versus percutaneous tibial nerve stimulation in women with overactive bladder syndrome: results of a randomized controlled crossover study. Gynecol Obstet Invest. 2013;75(4):230-4. doi: 10.1159/000350216. Epub 2013 Mar 28. PubMed PMID: 23548260.
8: Singh L, Nanda S. Spectrophotometric estimation of solifenacin succinate in tablet formulations. Pharm Methods. 2011 Jan;2(1):21-4. doi: 10.4103/2229-4708.81086. PubMed PMID: 23781425; PubMed Central PMCID: PMC3658025.
9: Krishna SR, Rao BM, Rao NS. A validated rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography. J Chromatogr Sci. 2010 Nov;48(10):807-10. PubMed PMID: 21044410.
10: Ohtake A, Sato S, Sasamata M, Miyata K. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes. J Pharmacol Sci. 2010;112(2):135-41. Epub 2010 Feb 4. Review. PubMed PMID: 20134114.
Related CAS#
CAS#242478-38-2 (Solifenacin succinate);
CAS#242478-37-1 (Solifenacin free base).
